Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
Phase 1 Completed
18 enrolled
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Phase 2 Completed
118 enrolled 14 charts
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
Phase 1 Completed
Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas
Phase 2 Completed
Collecting Solid Tumor Tissue to Identify New Treatments
Completed
133 enrolled
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Phase 2 Completed
10 enrolled 14 charts
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Phase 1/2 Completed
40 enrolled 37 charts
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Phase 1/2 Completed
134 enrolled 12 charts
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
Phase 1/2 Completed
65 enrolled 17 charts
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
Phase 2 Completed
154 enrolled
Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
Phase 2 Completed
82 enrolled
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Completed
46 enrolled 13 charts
Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
Phase 1 Completed
7 enrolled 17 charts
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
Phase 1/2 Completed
55 enrolled 22 charts
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
Phase 2 Completed
19 enrolled 7 charts
TKM 080301 for Primary or Secondary Liver Cancer
Phase 1 Completed
1 enrolled
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
Phase 1 Completed
98 enrolled
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Phase 2 Completed
73 enrolled 11 charts
Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
Phase 2 Completed
15 enrolled 11 charts
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Phase 1 Completed
42 enrolled
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Phase 1 Completed
43 enrolled
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
Phase 2 Completed
51 enrolled 10 charts
Immunotoxin Therapy in Treating Patients With Advanced Cancer
Phase 1 Completed
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Phase 2 Completed
52 enrolled 8 charts
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
20 enrolled
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
Phase 2 Completed
18 enrolled 10 charts
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer
Phase 2 Completed
21 enrolled 9 charts
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Phase 1/2 Completed
66 enrolled
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
Phase 2 Completed
10 enrolled 9 charts
Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery
Phase 2 Completed
137 enrolled 8 charts
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
Phase 2 Completed
143 enrolled 9 charts
Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors
Phase 1 Completed
37 enrolled
Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
18 enrolled
Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer
Phase 3 Completed
1,030 enrolled
Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Phase 2 Completed
88 enrolled
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
Phase 2 Completed
116 enrolled
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Phase 1 Completed
41 enrolled
Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase 3 Completed
1,110 enrolled
Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery
Phase 2 Completed
254 enrolled
Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Completed
120 enrolled
3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
Phase 2 Completed
Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer
Phase 2 Completed
48 enrolled
Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
Phase 2 Completed
50 enrolled
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
Phase 2 Completed
40 enrolled
Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer
Phase 2 Completed
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Completed
35 enrolled
Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase 3 Completed
508 enrolled
Alanosine in Treating Patients With Cancer
Phase 2 Completed